Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migration

GP-2250 demonstrated ability to downregulate protein expression of aberrant tumorigenic pathways in virus-negative MCC cell lines

Excerpt from the Press Release:

BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced the publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel cell carcinoma cells: preliminary results¹,” in the peer-reviewed Journal of Cancer Research and Clinical Oncology.

The objective of the preclinical study was to investigate the effects of GP-2250 on Merkel cell polyomavirus (MCPyV)-negative MCC cells. Patients with MCPyV-negative MCC have a much lower 5-year survival rate than MCPyV-positive cancer.

Greg Bosch, Chairman and CEO of Panavance Therapeutics commented, “We are encouraged by these preclinical findings in this rare, aggressive form of skin cancer. These preliminary results demonstrating the effectiveness of GP-2250 on MCC represent the second neuroendocrine cancer in which GP-2250 has shown effectiveness, the other one being pancreatic neuroendocrine cancer.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release